Form 4: Edwards Lifesciences VP Receives Major Equity Awards

Wayne Markowitz, Corporate Vice President at Edwards Lifesciences, received significant equity awards including stock options and performance rights while selling a portion of existing holdings.

Summary

• Wayne Markowitz (CVP, JAPAC) was granted 5,200 restricted stock units (RSUs) on May 7, 2026.
• The executive received 26,400 employee stock options with an exercise price of $82.76.
• A target award of 5,200 performance rights was granted, vesting in 2029 based on specific performance metrics.
• Markowitz sold 593 shares at $79.73 and had a total of 490 shares withheld for tax obligations across two dates.
• Following these transactions, the reporting person directly owns 21,679.8708 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a standard but positive reinforcement of executive alignment with long-term shareholder value through performance-linked equity.

Positives

• Grant of 26,400 stock options aligns executive incentives with long-term share price appreciation.
• Performance rights (5,200 target) link compensation to specific corporate goals over a three-year period.
• The executive maintains a significant direct ownership stake exceeding 21,000 shares.

Negatives

• The executive executed an open-market sale of 593 shares at a price of $79.73.
• A total of 490 shares were disposed of to satisfy tax withholding requirements, slightly reducing net equity retention.

Risks

• Performance rights are subject to 0% vesting if three-year performance goals are not achieved by 2029.
• Stock options only provide value if the market price exceeds the $82.76 exercise price during the exercise window.

Future Outlook

The executive's compensation is heavily weighted toward long-term performance and retention, with vesting schedules for new grants extending through 2030 for options and 2029 for performance units.

Management Comments

• The equity grants were issued under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.

Industry Context

StockSavvy.ai notes that these equity structures are typical for large-cap medical technology firms aiming to retain talent and drive performance in high-growth international markets like JAPAC.

Comparison to Industry Standards

• Vesting periods of four years are standard for industry peers such as Medtronic and Boston Scientific.
• The 0% to 200% performance multiplier for rights is a common benchmark for executive long-term incentive plans (LTIPs) in the S&P 500 healthcare sector.

Stakeholder Impact

• Shareholders may view the performance-linked grants as a positive mechanism to ensure management focuses on long-term growth.

Next Steps

• Monitor for the first vesting installment of RSUs and options in May 2027.
• Track achievement of performance goals related to the 2029 performance unit cliff vest.

Key Dates

Recommendation

This is a routine administrative filing regarding executive compensation and does not signal a fundamental change in the company's valuation or strategic direction.

Keywords

Edwards Lifesciences, EW, Executive Compensation, Insider Trading, Stock Options, Restricted Stock Units, Medical Devices, JAPAC